Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Demaria, Sandra ^a   Pilones, Karsten A ^a   Formenti, Silvia C ^a   Dustin, Michael L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abscopal effect; CTLA 4; Ipilimumab; NKG2D; Radiotherapy; RAE 1; Synergy; Tumor rejection

Indexed keywords

CELL PROTEIN; CHEMOKINE RECEPTOR CXCR6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; RETINOIC ACID EARLY INDUCIBLE 1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INTRACELLULAR SIGNALING; IONIZING RADIATION; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; RADIATION RESPONSE; RADIOSENSITIZATION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 84886944998     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23127     Document Type: Article

References (10)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
2. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34; PMID:15701862.
3. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immunemediated abscopal effect when combined with anti- CTLA-4 antibody. Clin Cancer Res 2009; 15:5379-88; PMID:19706802; http://dx.doi.org/10.1158/1078-0432.CCR-09-0265.
4. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824.
5. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009; 10:718-26; PMID:19573801; http://dx.doi.org/10.1016/S1470-2045(09)70082-8.
6. Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest 2012; 122:3718-30; PMID:22945631; http://dx.doi.org/10.1172/JCI61931.
7. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980.
8. Breart B, Lemaître F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 2008; 118:1390-7; PMID:18357341; http://dx.doi.org/10.1172/JCI34388.
9. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313:1972-5; PMID:16931720; http://dx.doi.org/10.1126/science.1131078.
10. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008; 224:141-65; PMID:18759925; http://dx.doi.org/10.1111/j.1600-065X.2008.00649.x.